ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
Study sponsor: Aldeyra Therapeutics, Inc. · ALDX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2018-11-05Actual
Enrollment · participants318Actual
Source updated2025-02-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.